The Food and Drug Administration said a Covid-19 antibody treatment from Eli Lilly & Co. is no longer authorized for use because it isn’t likely to be effective against certain Omicron offshoots now dominant in the U.S.
from Eli Lilly & Co. is no longer authorized for use because it isn’t likely to be effective against certain Omicron offshoots now dominant in the U.S.
, now cause more than half of new Covid-19 cases in the U.S., the FDA said on Wednesday. Yet Lilly’s drug, bebtelovimab, doesn’t retain neutralizing activity against the subvariants, the company said.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Survey: How many people plan to get the bivalent COVID-19 omicron booster shot?The elderly are at higher risk for severe COVID-19. In the BW poll, 63.7% said they would get the booster, while 17.9% said no and 18.5% were unsure.
Baca lebih lajut »
COVID hospitalization rates in babies as bad as for seniors amid Omicron wave, study showsThe findings, published by the U.S. Centers for Disease Control and Prevention, show that COVID-19 can still cause severe and fatal outcomes in children too young to be vaccinated.
Baca lebih lajut »
Can China end its ‘zero COVID’ policy — and minimize COVID deaths?Vaccinating more older people, stocking up on antiviral drugs and expanding hospital facilities would help to ease the transition away from zero COVID.
Baca lebih lajut »
Diabetes Drug Metformin Might Keep Severe COVID AwayA century-old diabetes drug seems to help keep high-risk COVID-19 patients from falling deathly ill, a new study reports.
Baca lebih lajut »